Literature DB >> 32220548

Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer.

Francesca Sanguedolce1, Ugo Giovanni Falagario2, Pietro Castellan3, Michele Di Nauta4, Giovanni Silecchia4, Salvatore M Bruno4, Davide Russo1, Patrick-Julien Treacy5, Ashutosh K Tewari5, Rodolfo Montironi6, Giuseppe Carrieri4, Luigi Cormio4.   

Abstract

PURPOSE: To determine the potential role of bioptic inflammation (Irani score) in predicting adverse pathology (AP) at radical prostatectomy (RP) in patients with low-grade (ISUP Gleason Group [ISUP GG] 1 and 2) prostate cancer (CaP).
METHODS: After institutional review board-approval, we identified patients who underwent prostate biopsy, had bioptic Irani score assessment, were diagnosed with low-grade CaP (ISUP GG 1-2, prostate-specific antigen [PSA] <20 ng/ml), and underwent RP. The impact of standard clinicopathological variables and bioptic Irani Score (G = grade and A = aggressiveness) on AP at RP, defined as stage ≥T3 and/or ISUP GG ≥3, was assessed by univariate and multivariate logistic regression analysis.
RESULTS: A total of 282 patients were eligible for this study. AP at RP occurred in 37 of 214 (17.3%) patients with ISUP GG 1, and 26 of 68 (38.2%) with ISUP GG 2. At univariate analysis, serum PSA, PSA density, bioptic ISUP GG, number of positive cores, total percentage of core involvement and Irani G score emerged as significant risk factors of AP. At multivariate analysis, however, only PSA density, bioptic ISUP GG, total percentage of core, and Irani G score kept statistical significance. The area under the curve for the resulting model was 0.75.
CONCLUSIONS: This is the first study demonstrating that low-grade inflammation is associated with a significantly increased risk of AP at RP. These findings would support the concept of prostatic inflammation being inversely correlated with presence and aggressiveness of CaP. Further studies are needed to externally validate the role of this readily available parameter in the decision-making process of patients with low-grade CaP.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Active surveillance; Low grade prostate biopsy; Prostate cancer; Prostatic inflammation; Radical prostatectomy; Upgrading

Mesh:

Substances:

Year:  2020        PMID: 32220548     DOI: 10.1016/j.urolonc.2020.02.025

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

1.  Utility of Clinical-Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions.

Authors:  Pengfei Jin; Liqin Yang; Xiaomeng Qiao; Chunhong Hu; Chenhan Hu; Ximing Wang; Jie Bao
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

2.  Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data.

Authors:  Tao Tao; Changming Wang; Weiyong Liu; Lei Yuan; Qingyu Ge; Lang Zhang; Biming He; Lei Wang; Ling Wang; Caiping Xiang; Haifeng Wang; Shuqiu Chen; Jun Xiao
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

3.  PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study.

Authors:  Salvatore M Bruno; Ugo G Falagario; Nicola d'Altilia; Marco Recchia; Vito Mancini; Oscar Selvaggio; Francesca Sanguedolce; Francesco Del Giudice; Martina Maggi; Matteo Ferro; Angelo Porreca; Alessandro Sciarra; Ettore De Berardinis; Carlo Bettocchi; Gian Maria Busetto; Luigi Cormio; Giuseppe Carrieri
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

4.  Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways.

Authors:  Yufei Liu; Chen Yang; Zheyu Zhang; Haowen Jiang
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

5.  Computational analysis of eugenol inhibitory activity in lipoxygenase and cyclooxygenase pathways.

Authors:  Francisco das Chagas Pereira de Andrade; Anderson Nogueira Mendes
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.